Early hematopoietic stem cell transplant is associated with favorable outcomes in children with MDS.
- Citation data:
Pediatric blood & cancer, ISSN: 1545-5017, Vol: 60, Issue: 4, Page: 705-10
- Publication Year:
- Most Recent Tweet View All Tweets
Although hematopoietic stem cell transplantation (HSCT) is the treatment of choice for childhood myelodysplastic syndrome (MDS), there is no consensus regarding patient or disease characteristics that predict outcomes.